期刊文献+

帕利哌酮缓释片和奋乃静对首发精神分裂症患者认知功能的影响 被引量:10

下载PDF
导出
摘要 目的:探讨帕利哌酮缓释片和奋乃静对首发精神分裂症患者认知功能的影响。方法:将100例首发精神分裂症患者随机均分为帕利哌酮缓释片组和奋乃静组,在治疗前和治疗12周后进行7个神经心理测验(共17项指标)用以评估患者的执行功能、注意力、言语学习和记忆以及分言语学习和记忆。结果:治疗第12周末,帕利哌酮缓释片组除Stroop-c、连线测验A和数字广度测验-顺背外其它各项认知功能指标均有所好转,而奋乃静组共有7项指标恶化,包括即刻和延迟逻辑记忆、Stroop-CW、TMT-B、数字广度测验-倒背、即刻和延迟视觉再生;帕利哌酮缓释片组绝大多数认知功能测查结果优于奋乃静组(P<0.05)。结论:帕利哌酮缓释片对首发精神分裂症患者的认知功能有改善作用,而奋乃静对认知功能的某些方面有损害。
出处 《陕西医学杂志》 CAS 2013年第9期1195-1197,共3页 Shaanxi Medical Journal
  • 相关文献

参考文献8

  • 1杜永慧,苏辉,沈辉,费慧,王丽华,陈妍.奥氮平与利培酮对精神分裂症认知功能影响的对照研究[J].神经疾病与精神卫生,2011,11(6):580-582. 被引量:8
  • 2Henry-Sliver B, Med S, Pablo F. Working memory bef- icit as a core neuropsychological dysfunction in schizo- phreniaFJ. Am J Psychiatry,2003,160(10 ) :1809-1816.
  • 3高作惠,严峻,王鹏,李长风.齐拉西酮对首发精神分裂症患者认知功能的影响[J].公共卫生与预防医学,2011,22(1):97-98. 被引量:7
  • 4Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oraldelivery system (OROS), an advanced oral delivery formJ]. Curt Med Res Opin,2006,22(10) . 1879-1893.
  • 5Millan MJ, Cara BD, Dekeyne A, etal. Selective block- ade of dopamine Da versus Dz receptors enhances fronto- cortical eholinergic transmission and social memory in rats., a parallel neurochemical and behavioural analysis [J]. Journal of Neurochemistry, 2007, 100.1047-1061.
  • 6Seeman P. An update of fast-off dopamine De atypical antipsychoticsI-J. Am J Psychiatry , 2005, 162 (10) : 1984 1985.
  • 7Turkoz I, Bossie CA, Lindenmayer JP, et al. Paliperi- done ER and oral risperidone in patients with schizophrenia: a comparative database analysis[-J]. BMC Psychia- try, 2011,11(1) :21-23.
  • 8Meltzer HY, Bobo WV, Nuamah IF, etal. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week, placebo-controlled studies[J. Clin Psychi- atry, 2008,69(5). 817-829.

二级参考文献16

  • 1高桂林,陈莉.奥氮平治疗首发精神分裂症的疗效分析[J].上海精神医学,2003,15(1):33-34. 被引量:29
  • 2白艳乐,江开达,王立伟,昂秋青.非典型抗精神病药物与认知功能[J].上海精神医学,2003,15(3):183-186. 被引量:20
  • 3王任昌,刘锡英.氯丙嗪、利培酮和阿立派唑对精神分裂症患者认知功能作用的比较[J].中国行为医学科学,2006,15(7):620-620. 被引量:19
  • 4张宝山,马和增,张敏,房崇村,王力刚.齐拉西酮与喹硫平治疗以阴性症状为主的精神分裂症对照研究[J].精神医学杂志,2007,20(1):14-16. 被引量:24
  • 5Robert R Conley, Ramy Mahmoud. A randomized double -- blindstudy of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder[J]. Am J Psychiatry, 2001,158(5) :765 -774.
  • 6Stipe E, Remington GI, Dursun SM, et al. Aeanadian multi- center trial assessing memory and executive functions in pa- tients with schizophrenia spectrum disorders treated with olanzapine[J]. J Clin Psychopharmacol, 2003, 23 (4) : 400 -- 404.
  • 7Mcgurk SR,Cameron C, Robert G,et al. The Effects of Cloza- pine and Risperidone on Spatial Working Memory in Schizo- phrenia[J]. Am J Psychiatry, 2005,162 (5) : 1 013 -- 1 016.
  • 8Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine olanzapine, risperidone, and halopefidol in patients with ehronie schizophrenia or schizo affeetive disorder [J]. Am J Psychiatry,2002,159(12) :2 118--2 119.
  • 9Hong KS,Kim JG, Koh H J, et al. Effects of risperidone on in- formation processing and attention in first -- episode sehizo- phrenia[J]. Schizophrenia Research, 2002,53 (1) : 7-- 16.
  • 10Crespo FB, Prez IR, Ramirez BM, et al. A practical clinical tri- al comparing halopefidol, risperidone, and olanzapine for the a- cute treatment of first episode nonaffective psychosis[J]. J Clin Psychiatry,2006,67(10) :1 511--1 521.

共引文献13

同被引文献75

  • 1杨海晨,刘铁榜,杨孔军,吴怀安.氯氮平与难治性精神分裂症[J].临床精神医学杂志,2006,16(5):310-311. 被引量:9
  • 2中华医学会精神科分会.中国精神障碍分类与诊断标准:CCMD-3[M].3版.济南:山东科学技术出版社,2001:87-89.
  • 3张作记.行为医学量表手册[M].北京:中国行为医学科学杂志社,2001.104-106.
  • 4陈旭先,司天梅.精神分裂症患者氯氮平使用现况调查[J].临床精神医学杂志,2007,17(6):394-396. 被引量:10
  • 5Stip E.Cognition,schizophrenia and the effect of antipsychotics[J].Encephale,2006,32(3):341.
  • 6Lindenmayer JP,Harvey PD,Khan A,et al.Schizophrenia:measurements of psychopathology psychiatry[J].Psychiatr Clin North Am,2007,30(3):339.
  • 7Maat A,Fett AK,Derks E,et al.Social cognition and quality of life in schizophrenia[J].Schizophr Res,2012,137(1/2/3):212.
  • 8Sidlova M,Prasko J,Jelenova D,et al.The quality of life of patients suffering from schizophrenia:comparison with healthy controls[J].Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2011,155(2):173.
  • 9Kucharska-Pietura K,Mortimer A,Tylec A,et al.Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs[J].Clin Schizophr Relat Psychoses,2012,6(1):14.
  • 10Green MF,Nuechtedein KH,Gold JM,et al.Approaching a consensus cognitive battery for clinical trials in schizophrenia:the NIMH-MATRICS conference to select cognitive domains and criteria[J].Biol Psychiatry,2004,56(5):301.

引证文献10

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部